Skip to main content

Drug Interactions between Aptivus and atrasentan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

tipranavir atrasentan

Applies to: Aptivus (tipranavir) and atrasentan

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.

MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.

Drug and food interactions

Moderate

tipranavir food

Applies to: Aptivus (tipranavir)

Tipranavir should be taken with food. This helps to reduce the gastrointestinal side effects of ritonavir, which you must also take with tipranavir in order to achieve effective blood levels of the medication against HIV. Talk to your doctor or pharmacist if you have any questions on how to use these medications properly.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer